The Experts below are selected from a list of 303 Experts worldwide ranked by ideXlab platform
Brian G Keevil - One of the best experts on this subject based on the ideXlab platform.
-
Therapeutic Drug Monitoring and lc ms ms
Journal of Chromatography B, 2012Co-Authors: Joanne E Adaway, Brian G KeevilAbstract:LC-MS/MS is an increasingly important tool in Therapeutic Drug Monitoring as it offers increased sensitivity and specificity compared to other methods, and may be the only viable method for quantifying Drugs without natural chromophores or fluorophores. The choice of sample preparation method, column technology, internal standard and mass spectrometric conditions is important to ensure accurate Drug measurement and to avoid interference from matrix effects and Drug metabolites. LC-MS/MS is a more involved technique than automated immunoassays, but technological advances such as the development of pipetting robots and online solid phase extraction mean that LC-MS/MS is becoming an attractive and convenient method for Therapeutic Drug Monitoring in clinical laboratories.
-
Therapeutic Drug Monitoring and LC-MS/MS.
Journal of chromatography. B Analytical technologies in the biomedical and life sciences, 2011Co-Authors: Joanne E Adaway, Brian G KeevilAbstract:LC-MS/MS is an increasingly important tool in Therapeutic Drug Monitoring as it offers increased sensitivity and specificity compared to other methods, and may be the only viable method for quantifying Drugs without natural chromophores or fluorophores. The choice of sample preparation method, column technology, internal standard and mass spectrometric conditions is important to ensure accurate Drug measurement and to avoid interference from matrix effects and Drug metabolites. LC-MS/MS is a more involved technique than automated immunoassays, but technological advances such as the development of pipetting robots and online solid phase extraction mean that LC-MS/MS is becoming an attractive and convenient method for Therapeutic Drug Monitoring in clinical laboratories.
Pierre Marquet - One of the best experts on this subject based on the ideXlab platform.
-
Ribavirin Therapeutic Drug Monitoring: why, when and how?
Fundamental & clinical pharmacology, 2009Co-Authors: Françoise Stanke-labesque, Véronique Loustaud-ratti, G. Babany, Marie-claude Gagnieu, Pierre MarquetAbstract:Recent studies suggest the potential interest of ribavirin Therapeutic Drug Monitoring to improve sustain virological response rate in hepatitis C virus-infected patients. The present review details the pharmacokinetic properties of ribavirin, suggesting that it may be a good candidate for Therapeutic Drug Monitoring, the different possible strategies and the analytical methods that could be employed.
-
Current role of LC-MS in Therapeutic Drug Monitoring
Analytical and Bioanalytical Chemistry, 2007Co-Authors: Franck Saint-marcoux, François-ludovic Sauvage, Pierre MarquetAbstract:The role of liquid chromatography coupled with mass spectrometry (LC-MS) techniques in routine Therapeutic Drug Monitoring activity is becoming increasingly important. This paper reviews LC-MS methods published in the last few years for certain classes of Drugs subject to Therapeutic Drug Monitoring: immunosuppressants, antifungal Drugs, antiretroviral Drugs, antidepressants and antipsychotics. For each class of compounds, we focussed on the most interesting methods and evaluated the current role of LC-MS in Therapeutic Drug Monitoring.
Joanne E Adaway - One of the best experts on this subject based on the ideXlab platform.
-
Therapeutic Drug Monitoring and lc ms ms
Journal of Chromatography B, 2012Co-Authors: Joanne E Adaway, Brian G KeevilAbstract:LC-MS/MS is an increasingly important tool in Therapeutic Drug Monitoring as it offers increased sensitivity and specificity compared to other methods, and may be the only viable method for quantifying Drugs without natural chromophores or fluorophores. The choice of sample preparation method, column technology, internal standard and mass spectrometric conditions is important to ensure accurate Drug measurement and to avoid interference from matrix effects and Drug metabolites. LC-MS/MS is a more involved technique than automated immunoassays, but technological advances such as the development of pipetting robots and online solid phase extraction mean that LC-MS/MS is becoming an attractive and convenient method for Therapeutic Drug Monitoring in clinical laboratories.
-
Therapeutic Drug Monitoring and LC-MS/MS.
Journal of chromatography. B Analytical technologies in the biomedical and life sciences, 2011Co-Authors: Joanne E Adaway, Brian G KeevilAbstract:LC-MS/MS is an increasingly important tool in Therapeutic Drug Monitoring as it offers increased sensitivity and specificity compared to other methods, and may be the only viable method for quantifying Drugs without natural chromophores or fluorophores. The choice of sample preparation method, column technology, internal standard and mass spectrometric conditions is important to ensure accurate Drug measurement and to avoid interference from matrix effects and Drug metabolites. LC-MS/MS is a more involved technique than automated immunoassays, but technological advances such as the development of pipetting robots and online solid phase extraction mean that LC-MS/MS is becoming an attractive and convenient method for Therapeutic Drug Monitoring in clinical laboratories.
David M. Burger - One of the best experts on this subject based on the ideXlab platform.
-
Therapeutic Drug Monitoring of voriconazole.
Therapeutic drug monitoring, 2008Co-Authors: Roger J. M. Brüggemann, Rob E. Aarnoutse, J. Peter Donnelly, Adilia Warris, Nicole M. A. Blijlevens, Johan W. Mouton, Paul E. Verweij, David M. BurgerAbstract:Voriconazole is a triazole antifungal developed for the treatment of life-threatening fungal infections in immunocompromised patients. The Drug, which is available for both oral and intravenous administration, has broad-spectrum activity against pathogenic yeasts, dimorphic fungi, and opportunistic molds. Voriconazole has a nonlinear pharmacokinetic profile with a wide inter- and intraindividual variety. This variability is caused by many factors such as gender, age, genotypic variation, liver dysfunction, the presence of food, and so on. Another important factor influencing voriconazole's pharmacokinetic profile is Drug-Drug interactions with CYP450 inhibitors as well as inducers. Variability in plasma concentrations, as a result of the previously mentioned aspects, may lead to variability in efficacy or toxicity. Determination of plasma concentrations is indicated in situations to guide dosing and to individualize and improve the treatment options resulting in better Therapeutic outcome or fewer side effects. In this article, we review factors influencing voriconazole pharmacokinetic profile, the data supporting exposure-effect and exposure-toxicity relationships, review the gaps in current knowledge, which make broad recommendations for Therapeutic Drug Monitoring difficult for voriconazole, provide the indications in which Therapeutic Drug Monitoring is reasonable based on currently available data (eg, children), and outline the ways in which this problem could be solved. We provide a summary of the problem so that further research can be conducted to address this are of clinical need.
-
Use of Therapeutic Drug Monitoring in HIV disease.
Current opinion in HIV and AIDS, 2008Co-Authors: Matthijs Van Luin, Paul F M Kuks, David M. BurgerAbstract:Therapeutic Drug Monitoring is frequently used in several European countries, and international guidelines recommend it in selected cases. We discuss the main arguments for and against Therapeutic Drug Monitoring in HIV infection. Accumulating evidence favours the use of Therapeutic Drug Monitoring in the management of Drug concentration-related toxicities. Interindividual variability in the pharmacokinetics of antiretroviral Drugs is at least partially caused by genetic polymorphisms. Additionally, body weight, sex and ethnicity have been identified as independent predictors of pharmacokinetics. Several studies have revealed subTherapeutic Drug concentrations in children who were treated in accordance with the label information, which is in favour of Therapeutic Drug Monitoring in children. The inhibitory quotient concept has been further explored, but more work is needed to justify full implementation into routine clinical practice. A limitation of Therapeutic Drug Monitoring is the significant intraindividual variability in protease inhibitor concentrations. Furthermore, there is a lack of sufficiently powered randomized controlled trials that assess the use of routine Therapeutic Drug Monitoring for current first-line antiretroviral Drugs. Although routine Therapeutic Drug Monitoring cannot be recommended for current first-line antiretroviral Drugs, there are many frequently encountered clinical situations in which Therapeutic Drug Monitoring provides valuable information.
-
Pros and cons of Therapeutic Drug Monitoring of antiretroviral agents.
Current opinion in infectious diseases, 2002Co-Authors: David M. Burger, Rob E. Aarnoutse, P.w.h. HugenAbstract:Therapeutic Drug Monitoring has the promise to become a part of routine patient care in the treatment of HIV infection. It is known that plasma Drug concentrations of protease inhibitors and non-nucleoside reverse transcriptase inhibitors are better predictors of antiviral response or toxicity than Drug dose is. Furthermore, high interpatient variability is significant. In addition, Therapeutic Drug Monitoring may be used as a direct and objective instrument to measure non-adherence. This review describes possibilities and limitations of Therapeutic Drug Monitoring in HIV treatment.
Amitava Dasgupta - One of the best experts on this subject based on the ideXlab platform.
-
Therapeutic Drug Monitoring of antimicrobial, antifungal and antiviral agents
Therapeutic Drug Monitoring Data, 2020Co-Authors: Amitava Dasgupta, Matthew D. KrasowskiAbstract:Abstract The word antibiotic comes from Greek words “anti” means against and “bios” meaning life. The first effective antibiotic discovered was penicillin. After the discovery of penicillin > 100 antibiotics have been developed and currently used in medicine. Antibiotics can be classified based on their chemical structures or on the basis of mechanism. Although most antibiotics do not require routine Therapeutic Drug Monitoring, some antibiotics have narrow Therapeutic ranges and require routine Monitoring. Vancomycin and aminoglycosides require routine Monitoring during therapy due to their known ototoxicity and nephrotoxicity. Other toxic antibiotic such as chloramphenicol requires Monitoring along with few other antibiotics. Some antifungal Drugs may benefit from Monitoring. For certain antiretrovirals such as protease inhibitors routine Therapeutic Drug Monitoring may also be beneficial. Monographs of these Drugs requiring Therapeutic Drug Monitoring are included in this chapter.
-
Resolving erroneous reports in toxicology and Therapeutic Drug Monitoring
2014Co-Authors: Amitava DasguptaAbstract:Resolving erroneous reports in toxicology and Therapeutic Drug Monitoring : , Resolving erroneous reports in toxicology and Therapeutic Drug Monitoring : , کتابخانه دیجیتال جندی شاپور اهواز
-
Chapter 14 – Therapeutic Drug Monitoring
Clinical Chemistry Immunology and Laboratory Quality Control, 2014Co-Authors: Amitava DasguptaAbstract:Only a small fraction of Drugs (approximately 50) out of over 3,000 prescription Drugs require Therapeutic Drug Monitoring; usually 20–30 Drugs are routinely monitored in most hospital laboratories. Immunoassays are available for Monitoring 26 Drugs, while for Monitoring less frequently ordered Drugs, chromatographic techniques must be used. Usually Therapeutic Drug Monitoring (TDM) is conducted using a trough specimen, although for TDM of vancomycin and aminoglycosides both peak and trough Monitoring may be necessary. TDM must be conducted after a Drug reaches its steady state (which requires approximately five half-lives). This chapter will address frequently and less frequently monitored Drugs along with basic pharmacokinetics.
-
Interferences in Therapeutic Drug Monitoring
Clinical Chemistry Immunology and Laboratory Quality Control, 2014Co-Authors: Amitava Dasgupta, Amer WahedAbstract:Immunoassays used for Therapeutic Drug Monitoring (TDM) are subjected to interferences from structurally similar compounds and metabolites of the parent Drug. Immunoassays for digoxin are mostly affected and digoxin values may be falsely elevated (or, rarely, falsely lower) due to such interferences. Digoxin immunoassays are affected by endogenous digoxin-like immunoreactive substances (DLIS), spironolactone, potassium canrenoate, as well as various herbal supplements. Significant metabolite cross-reactivity in the immunoassays for various immunosuppressants is a serious problem. This chapter will summarize various aspects of interferences in TDM using immunoassays.
-
Impact of interferences including metabolite crossreactivity on Therapeutic Drug Monitoring results.
Therapeutic drug monitoring, 2012Co-Authors: Amitava DasguptaAbstract:Therapeutic Drug Monitoring is an integral part of services offered by toxicology laboratories because certain Drugs require routine Monitoring for dosage adjustment to achieve optimal Therapeutic response and avoid adverse Drug reactions. Immunoassays are widely used for Therapeutic Drug Monitoring. However, immunoassays suffer from interferences from both exogenous and endogenous compounds including metabolites of the parent Drug. Digoxin immunoassays are affected more commonly than any other immunoassays used for Therapeutic Drug Monitoring. Digoxin immunoassays are affected by endogenous digoxin-like immunoreactive substances and exogenous compounds such as various Drugs, certain herbal supplements, and Digibind. Carbamazepine is metabolized to carbamazepine 10, 11-epoxide, and the crossreactivity of this metabolite with carbamazepine immunoassay may vary from 0% to 94%. Immunoassays used for measuring concentrations of tricyclic antidepressants are affected by tricyclic antidepressant metabolites and by a number of other Drugs. Immunoassays for immunosuppressants are also subjected to significant interferences from metabolites, and liquid chromatography combined with mass spectrometry or tandem mass spectrometry is recommended for Therapeutic Drug Monitoring of immunosuppressants. However, liquid chromatography combined with mass spectrometry may also suffer from interferences, for example, due to ion suppression or from isobaric ions.
